1H-Indazol-4-amine, 1-methyl- → N-[4-(1-azepanyl)-3-fluorobenzyl]-N'-(1-methyl-1H-indazol-4-yl)urea
反応式
[F:1][C:2]1[CH:7]=[C:6]([CH2:8][N:9]=[C:10]=[O:11])[CH:5]=[CH:4][C:3]=1[N:12]1[CH2:18][CH2:17][CH2:16][CH2:15][CH2:14][CH2:13]1.[CH3:19][N:20]1[C:28]2[CH:27]=[CH:26][CH:25]=[C:24]([NH2:29])[C:23]=2[CH:22]=[N:21]1.N1C2C=CC=C(N)C=2C=N1>>[N:12]1([C:3]2[CH:4]=[CH:5][C:6]([CH2:8][NH:9][C:10]([NH:29][C:24]3[CH:25]=[CH:26][CH:27]=[C:28]4[C:23]=3[CH:22]=[N:21][N:20]4[CH3:19])=[O:11])=[CH:7][C:2]=2[F:1])[CH2:18][CH2:17][CH2:16][CH2:15][CH2:14][CH2:13]1参加物
4
実験手順
The title compound was prepared using the procedure described in Example 89B using 1-[2-fluoro-4-(isocyanatomethyl)phenyl]azepane and 1-methyl-1H-indazol-4-amine instead of 1-bromo-4-(isocyanatomethyl)benzene and the product from Example 89A. NMR (DMSO-d6) δ 9.03 (s, 1H), 8.19 (s, 1H), 7.67 (d, 1H), 7.24 (t, 1H), 7.12-6.95 (m, 5H), 4.22 (s, 2H), 3.99 (s, 3H), 3.35 (m, 4H), 1.78 (m, 4H), 1.55 (m, 4H); MS (ESI) (M+H)+ 396.